Genetic polymorphism in HCC patients treated with conventional Lipiodol-based trans-arterial chemo-embolization (TACE) using doxorubicin-lipiodol vs doxorubicin-loaded drug-eluting beads
| Gene | Total 40 | Lipiodol 20 | BEADs 20 | P-value | |
|---|---|---|---|---|---|
| ABCB1 | 0.004 | ||||
| C3435T | CC | 17 (42.5%) | 5 (29.4%) | 12 (70.59%) | |
| CT | 20 (50%) | 15 (75%) | 5 (25%) | ||
| TT | 3 (7.5%) | 0 (0%) | 3 (7.5%) | ||
| ABCG2 | 0.6 | ||||
| G34A | GG | 37 (92.5%) | 18 (48.6%) | 19 (51.3%) | |
| GA | 2 (5%) | 1 (50%) | 1 (50%) | ||
| AA | 1 (2.5%) | 1 (100%) | 0 (0%) | ||
| GSTM1 | Mutation present | 34 (85%) | 17 (85%) | 17 (85%) | 1 |
| Mutation absent | 6 (15%) | 3 (15%) | 3 (15%) | ||
| GSTT1 | Mutation present | 36 (90%) | 17 (85%) | 19 (95%) | 0.3 |
| Gene | Total 40 | Lipiodol 20 | BEADs 20 | ||
|---|---|---|---|---|---|
| ABCB1 | 0.004 | ||||
| C3435T | CC | 17 (42.5%) | 5 (29.4%) | 12 (70.59%) | |
| CT | 20 (50%) | 15 (75%) | 5 (25%) | ||
| TT | 3 (7.5%) | 0 (0%) | 3 (7.5%) | ||
| ABCG2 | 0.6 | ||||
| G34A | GG | 37 (92.5%) | 18 (48.6%) | 19 (51.3%) | |
| GA | 2 (5%) | 1 (50%) | 1 (50%) | ||
| AA | 1 (2.5%) | 1 (100%) | 0 (0%) | ||
| GSTM1 | Mutation present | 34 (85%) | 17 (85%) | 17 (85%) | 1 |
| Mutation absent | 6 (15%) | 3 (15%) | 3 (15%) | ||
| GSTT1 | Mutation present | 36 (90%) | 17 (85%) | 19 (95%) | 0.3 |
Source(s): Table by authors
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.